- Home
- FNWB vs IMAB Comparison
FNWB vs IMAB Comparison
Compare FNWB & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNWB
- IMAB
- Stock Information
- Founded
- FNWB 1923
- IMAB 2014
- Country
- FNWB United States
- IMAB United States
- Employees
- FNWB N/A
- IMAB N/A
- Industry
- FNWB Banks
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- FNWB Finance
- IMAB Health Care
- Exchange
- FNWB Nasdaq
- IMAB Nasdaq
- Market Cap
- FNWB 95.2M
- IMAB 79.9M
- IPO Year
- FNWB 2015
- IMAB 2020
- Fundamental
- Price
- FNWB $11.88
- IMAB $0.96
- Analyst Decision
- FNWB Hold
- IMAB Strong Buy
- Analyst Count
- FNWB 1
- IMAB 3
- Target Price
- FNWB $12.00
- IMAB $8.00
- AVG Volume (30 Days)
- FNWB 24.2K
- IMAB 286.0K
- Earning Date
- FNWB 01-29-2025
- IMAB 03-13-2025
- Dividend Yield
- FNWB 2.36%
- IMAB N/A
- EPS Growth
- FNWB N/A
- IMAB N/A
- EPS
- FNWB N/A
- IMAB N/A
- Revenue
- FNWB $50,900,000.00
- IMAB $569,464.00
- Revenue This Year
- FNWB N/A
- IMAB N/A
- Revenue Next Year
- FNWB $11.60
- IMAB N/A
- P/E Ratio
- FNWB N/A
- IMAB N/A
- Revenue Growth
- FNWB N/A
- IMAB N/A
- 52 Week Low
- FNWB $8.91
- IMAB $0.84
- 52 Week High
- FNWB $16.00
- IMAB $2.00
- Technical
- Relative Strength Index (RSI)
- FNWB 76.08
- IMAB 45.33
- Support Level
- FNWB $10.80
- IMAB $0.95
- Resistance Level
- FNWB $11.10
- IMAB $1.04
- Average True Range (ATR)
- FNWB 0.26
- IMAB 0.06
- MACD
- FNWB 0.10
- IMAB -0.01
- Stochastic Oscillator
- FNWB 90.14
- IMAB 19.88
About FNWB First Northwest Bancorp
First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It includes deposit and lending transactions that are supplemented with other borrowing and investing activities. The bank's principal lending activities are focused on first lien one- to four-family mortgage loans, commercial and multi-family real estate loans, construction and land loans, commercial business loans, and consumer loans.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).